Everolimus pharmacokinetics and its exposure–toxicity relationship in patients with thyroid cancer
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Everolimus pharmacokinetics and its exposure–toxicity relationship in patients with thyroid cancer
Authors
Keywords
Everolimus, Exposure–toxicity, Population pharmacokinetics, Pharmacogenetics, Individualized dosing
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 78, Issue 1, Pages 63-71
Publisher
Springer Nature
Online
2016-05-11
DOI
10.1007/s00280-016-3050-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Individualized dosing of tyrosine kinase inhibitors: are we there yet?
- (2015) Djoeke de Wit et al. DRUG DISCOVERY TODAY
- Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer
- (2014) M. Aapro et al. ANNALS OF ONCOLOGY
- Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours
- (2014) N A G Lankheet et al. BRITISH JOURNAL OF CANCER
- Impact of everolimus blood concentration on its anti-cancer activity in patients with metastatic renal cell carcinoma
- (2014) A. Thiery-Vuillemin et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets
- (2014) Huixin Yu et al. CLINICAL PHARMACOKINETICS
- Relationship between everolimus exposure and safety and efficacy: Meta-analysis of clinical trials in oncology
- (2013) Alain Ravaud et al. EUROPEAN JOURNAL OF CANCER
- Population Pharmacokinetics and Pharmacogenetics of Everolimus in Renal Transplant Patients
- (2012) Dirk Jan A.R. Moes et al. CLINICAL PHARMACOKINETICS
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regulation of CYP3A4 by pregnane X receptor: The role of nuclear receptors competing for response element binding
- (2010) Monica A. Istrate et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Mechanistic Basis of Using Body Size and Maturation to Predict Clearance in Humans
- (2009) Brian J. Anderson et al. Drug Metabolism and Pharmacokinetics
- Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity
- (2009) Nielka P. van Erp et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the mTOR Signaling Network for Cancer Therapy
- (2009) Funda Meric-Bernstam et al. JOURNAL OF CLINICAL ONCOLOGY
- Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration
- (2009) Albert-Jan L.H.J. Aarnoudse et al. Pharmacogenetics and Genomics
- Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data
- (2008) Chiaki Tanaka et al. JOURNAL OF CLINICAL ONCOLOGY
- Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors
- (2008) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors
- (2008) Anne O'Donnell et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started